| # | Title | Journal | Year | Citations |
|---|
| 1 | ROS stress in cancer cells and therapeutic implications | Drug Resistance Updates | 2004 | 1,686 |
| 2 | Aminoglycoside modifying enzymes | Drug Resistance Updates | 2010 | 1,007 |
| 3 | Overcoming the blood–brain tumor barrier for effective glioblastoma treatment | Drug Resistance Updates | 2015 | 706 |
| 4 | Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations | Drug Resistance Updates | 2008 | 698 |
| 5 | If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells | Drug Resistance Updates | 2001 | 625 |
| 6 | The modulation of ABC transporter-mediated multidrug resistance in cancer: A review of the past decade | Drug Resistance Updates | 2015 | 590 |
| 7 | Hypoxia-mediated drug resistance: Novel insights on the functional interaction of HIFs and cell death pathways | Drug Resistance Updates | 2011 | 512 |
| 8 | Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies | Drug Resistance Updates | 2016 | 511 |
| 9 | Activation of the PI3K/Akt pathway and chemotherapeutic resistance | Drug Resistance Updates | 2002 | 506 |
| 10 | Mechanisms and consequences of bacterial resistance to antimicrobial peptides | Drug Resistance Updates | 2016 | 491 |
| 11 | Sulfonamide resistance: mechanisms and trends | Drug Resistance Updates | 2000 | 486 |
| 12 | The increasing threat of Pseudomonas aeruginosa high-risk clones | Drug Resistance Updates | 2015 | 475 |
| 13 | Resistance to echinocandin-class antifungal drugs | Drug Resistance Updates | 2007 | 440 |
| 14 | Modulating ROS to overcome multidrug resistance in cancer | Drug Resistance Updates | 2018 | 420 |
| 15 | Nanomedicine for targeted cancer therapy: Towards the overcoming of drug resistance | Drug Resistance Updates | 2011 | 415 |
| 16 | RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature | Drug Resistance Updates | 2005 | 412 |
| 17 | Mechanisms of fluoroquinolone resistance | Drug Resistance Updates | 1999 | 400 |
| 18 | Cell survival, cell death and cell cycle pathways are interconnected: Implications for cancer therapy | Drug Resistance Updates | 2007 | 381 |
| 19 | Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and impact on treatment | Drug Resistance Updates | 2000 | 380 |
| 20 | The impact of antibiotic use on resistance development and persistence | Drug Resistance Updates | 2000 | 365 |
| 21 | The tumor microenvironment is a dominant force in multidrug resistance | Drug Resistance Updates | 2012 | 361 |
| 22 | Antifolates in cancer therapy: Structure, activity and mechanisms of drug resistance | Drug Resistance Updates | 2012 | 351 |
| 23 | DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity | Drug Resistance Updates | 2006 | 347 |
| 24 | How the Warburg effect supports aggressiveness and drug resistance of cancer cells? | Drug Resistance Updates | 2018 | 340 |
| 25 | Modifications of DNA by platinum complexes | Drug Resistance Updates | 2005 | 338 |
| 26 | Leishmaniasis: drugs in the clinic, resistance and new developments | Drug Resistance Updates | 2004 | 336 |
| 27 | Insights on antibiotic resistance of Staphylococcus aureus from its whole genome: genomic island SCC | Drug Resistance Updates | 2003 | 335 |
| 28 | Lysosomes as mediators of drug resistance in cancer | Drug Resistance Updates | 2016 | 330 |
| 29 | The multi-factorial nature of clinical multidrug resistance in cancer | Drug Resistance Updates | 2019 | 324 |
| 30 | ABC transporters as mediators of drug resistance and contributors to cancer cell biology | Drug Resistance Updates | 2016 | 316 |
| 31 | Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance | Drug Resistance Updates | 2010 | 313 |
| 32 | The folate receptor as a rational therapeutic target for personalized cancer treatment | Drug Resistance Updates | 2014 | 301 |
| 33 | Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine) | Drug Resistance Updates | 2002 | 297 |
| 34 | Clinical breakpoints for the echinocandins and Candida revisited: Integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria | Drug Resistance Updates | 2011 | 293 |
| 35 | Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers | Drug Resistance Updates | 2008 | 282 |
| 36 | Gemcitabine resistance in pancreatic ductal adenocarcinoma | Drug Resistance Updates | 2015 | 282 |
| 37 | The rapid spread of carbapenem-resistant Enterobacteriaceae | Drug Resistance Updates | 2016 | 282 |
| 38 | Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms | Drug Resistance Updates | 2002 | 277 |
| 39 | Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance | Drug Resistance Updates | 2020 | 275 |
| 40 | Mechanisms of proteasome inhibitor action and resistance in cancer | Drug Resistance Updates | 2008 | 272 |
| 41 | Collateral sensitivity as a strategy against cancer multidrug resistance | Drug Resistance Updates | 2012 | 269 |
| 42 | Antibiotic resistance in Pseudomonas aeruginosa – Mechanisms, epidemiology and evolution | Drug Resistance Updates | 2019 | 269 |
| 43 | Critical shortage of new antibiotics in development against multidrug-resistant bacteria—Time to react is now | Drug Resistance Updates | 2011 | 266 |
| 44 | Evolution of antibiotic resistance at non-lethal drug concentrations | Drug Resistance Updates | 2012 | 262 |
| 45 | International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus | Drug Resistance Updates | 2015 | 262 |
| 46 | Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance | Drug Resistance Updates | 2012 | 261 |
| 47 | Insights into the global molecular epidemiology of carbapenem non-susceptible clones of Acinetobacter baumannii | Drug Resistance Updates | 2012 | 261 |
| 48 | Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: Time for harmonization of CLSI and EUCAST broth microdilution methods | Drug Resistance Updates | 2010 | 259 |
| 49 | Blue light for infectious diseases: Propionibacterium acnes, Helicobacter pylori, and beyond? | Drug Resistance Updates | 2012 | 258 |
| 50 | Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria | Drug Resistance Updates | 2012 | 257 |
